ChemBK
  • Home
  • Product Category


Gefitinib impurity 2

Gefitinib impurity 2

CAS: 246512-44-7

Molecular Formula: C15H23N3O4

  1. Home
  2. Product Category
  3. Gefitinib impurity 2

Gefitinib impurity 2 - Names and Identifiers

Name Gefitinib impurity 2
Synonyms Gefitinib-12
Gefitinib impurity 2
Gefintinib Impurity 1
Gefitinib impurities129
2-aMino-4-Methoxy-5-(3-Morpholinopropoxy)benzaMide
2-Amino-4-methoxy-5-(3-morpholin-4-ylpropoxy)-benzamide
Benzamide, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propoxy]-
CAS 246512-44-7

Gefitinib impurity 2 - Physico-chemical Properties

Molecular FormulaC15H23N3O4
Molar Mass309.36
Density1.208±0.06 g/cm3(Predicted)
Melting Point153.5 °C
Boling Point460.6±45.0 °C(Predicted)
pKa15.86±0.50(Predicted)
Storage Condition2-8°C,密封,干燥

Gefitinib impurity 2 - Reference Information

biological activity Gefitinib importance 2 is an impurity of Gefitinib. Gefitinib (HY-50895) is a potent, orally active selective EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 54 nM) and blocks EGFR autophosphorylation in EGF-stimulated tumor cells. Gefitinib can also induce autophagy in cells. Gefitinib has anti-tumor activity.
Last Update:2024-04-09 15:16:57
Gefitinib impurity 2
Supplier List
MedChemExpress (MCE)
Spot supply
Product Name: Gefitinib impurity 2 Visit Supplier Webpage Request for quotation
CAS: 246512-44-7
Tel: 609-228-6898
Email: sales@medchemexpress.com
     tech@medchemexpress.com
Mobile: 609-228-6898
MedChemExpress (MCE)
Spot supply
Product Name: Gefitinib impurity 2 Visit Supplier Webpage Request for quotation
CAS: 246512-44-7
Tel: 609-228-6898
Email: sales@medchemexpress.com
     tech@medchemexpress.com
Mobile: 609-228-6898
View History
Gefitinib impurity 2
CarbaMic acid, (4-hydroxy-1-Methylcyclohexyl)-, 1,1-diMethylethyl ester
2,3-DICHLORONITROBENZENE PESTANAL, 250 M
更昔洛韦杂质814
1576-47-2
Benzothiamide
2-Chloro-3-Amino-6-(Trifluoromethyl) Pyridine
  • Home
  • Product Category

© 2015, 2023 ChemBK.com All Rights Reserved | Build: 20230617001